510(k) Report

510(k) · Cleared

Cleared

Aptima CT Assay on the Tigris DTS System

K061413510(k) TraditionalCleared Oct 13, 2006144-day reviewClass I21 CFR 866.3120

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Gen-Probe, Inc. · MKZ Dna Probe, Nucleic Acid Amplification, Chlamydia

Cleared on Oct 13, 2006 after a 144-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Oct 13, 2006
Review
144 days
Class
Class I
Product code
MKZ
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K061413Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MKZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MKZ device

  1. #1 K230451 Aptima® Chlamydia trachomatis Assayscore 6.4 · 1 generation · no Class I recall
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All MKZ devices

MKZ Dna Probe, Nucleic Acid Amplification, Chlamydia: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · MKZ

1in 2023

2007: 22008: 22009: 22012: 12014: 12023: 1
2007high 2 (2007) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MKZ

Too few MKZ 510(k)s in any year since 2007 to give a median.

Recalls per year · MKZ

1in 2010

2009: 12010: 1
2007high 1 (2009) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MKZ

1in 2025

2010: 12011: 92012: 12013: 62014: 22015: 12016: 12017: 62018: 32019: 32020: 72021: 92022: 22023: 42024: 72025: 1
2007high 9 (2011) · low 0 (2007)2025

MAUDE reports naming product code MKZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20082—00
20092—10
20100—11
20110—09
20121—01
20130—06
20141—02
20150—01
20160—01
20170—06
20180—03
20190—03
20200—07
20210—09
20220—02
20231—04
20240—07
20250—01
20260—0—

What is it indicated for?

The APTIMA Assay for Chlamydia trachomatis is a target amplification nucleix acid probe test that utilizes target capture for the in vitro qualitative detection of ribosomal RNA (rRNA) from Chlamydia trachomatis (CT) in clinician-collected endocervical, vaginal and male urethral swab specimens, patient-collected vaginal swab specimens, and female and male urine specimens. The assay may be used to test specimens from symptomatic and asymptomatic…

Read the full statement (113 words)

The APTIMA Assay for Chlamydia trachomatis is a target amplification nucleix acid probe test that utilizes target capture for the in vitro qualitative detection of ribosomal RNA (rRNA) from Chlamydia trachomatis (CT) in clinician-collected endocervical, vaginal and male urethral swab specimens, patient-collected vaginal swab specimens, and female and male urine specimens. The assay may be used to test specimens from symptomatic and asymptomatic individuals to aid in the diagnosis of chlamydial urogenital disease using the TIGRIS DTS Automated Analyzer or semi-automated instrumentation as specified.

Patient-collected vaginal swab specimens are an option for screening women when a pelvic exam is not otherwise indicated. The vaginal swab specimen collection kit is not for home use.

Indications for use as stated in the FDA 510(k) statement.

Cite this page

510(k) Report. “K061413: Aptima CT Assay on the Tigris DTS System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K061413

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026